https://www.selleckchem.com/products/icg-001.html
The survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characteristics of the patients in a population considered either eligible or ineligible for trials is unknown. The generalizability of trial results is therefore also uncertain. Using the Cancer Registry of Norway and the Brain Tumor Database at Oslo University
Like
Comment
Share
